Dermata must file a new drug application with the FDA.
2 reports, 1 independent
Updated Aug 14
Gone quiet
- Reports
- 2
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Dermata must file a new drug application with the FDA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Dermata pivoted learnings from prescription ingredients to a new brand, Tome. Tom Hale cofounded the company and remains involved in leadership.Sub-event
Dermata is required to submit a new drug application to the FDA.1 source
- Dermata's product is a topical botulinum toxin treatment.
Keep exploring
The entities involved
Related events
- The FDA recommended advancement for a new drug application submitted by a company.
- The FDA and European Medicines Agency are harmonizing regulatory review of drug applications.
- The FDA is currently reviewing new drug applications for market entry.
- Future sales of a product are contingent upon obtaining the necessary FDA registration and labeling, while the state simultaneously announces actions to remove regulatory barriers.
- The FDA requested additional clinical data from Unicycive Therapeutics.
Coverage
Newest first; wire copies grouped- ACCESS NewswireDermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - Dermata announced additional positive data from its XYNGARI™ Phase 3 Spongilla Treatment of Ac
- Unknown outlet